Marlowe Tessmer

Editors’ Picks, July 2025: U.S. Cancer Mortality Hotspots, Chemotherapy-induced Hearing Loss, and More In July 2025, the AACR's journals editors highlighted studies on U.S. cancer mortality hotspots, chemotherapy-induced hearing loss, and more.

Check out Editors' Picks from the July issues, covering cancer mortality hotspots in the US, the mechanisms of chemotherapy-induced hearing loss, and how AI might help pair patients with the right therapy and predict combination therapies that can prevent cancer escape. buff.ly/yK3WqW5

👉 Recently published in Clinical Cancer Research: A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy 🔗 doi.org/10.1158/1078... #EANOessentials #NeuroOncology #BrainMetastases #brainMets #medsky

If you are attending #AACRai25, meet the AACR Journals’ editors during breakfast on Friday, July 11th from 7AM – 8AM, featuring Kevin Burton, PhD, of Cancer Research, Emily Frieben, PhD, of Cancer Research Communications, and Tali Lev, PhD, of Cancer Discovery.

Image of a metastatic lymph node from a patient with oral squamous cell carcinoma. Multiplex immunohistochemical staining highlights the spatial interplay of PERK+ macrophages, activated fibroblasts & tumor cells in an immunosuppressive niche. Article by Zhang et al. aacrjournals.org/clincancerre...

Volume 31 Issue 9 | Clinical Cancer Research | American Association for Cancer Research

This snazzy image shows a region of pancreatic cysts, intraductal papillary mucinous neoplasms. The authors performed digital spatial transcriptomic profiling & found distinct indolent & malignant transcriptomic states. For more detail, see the article by Iyer et al. aacrjournals.org/clincancerre...

On day 4 of #AACR25 researchers shared data on combining liquid and tissue biopsies for tailored therapy selection, a decrease in breast cancer mortality, and clinical trial results for antibody-based therapies. Read more takeaways on the #AACRBlog: www.aacr.org/blog/2025/04...

Today is the day!!! Come by the #AACR25 booth to meet myself and Editor-in-Chief, Timothy Yap for Clinical Cancer Research. 2:00, booth #2615.

This is a potential game changer for many cancers.

Congratulations to Joseph C. Murray, MD, PhD, recipient of the 2025 Clinical Cancer Research Early Career Award, which recognizes the outstanding contributions of #earlycareer investigators. Learn more: brnw.ch/21wSfdm @hopkinspress.bsky.social @theaacr.bsky.social
#AACR25

Congratulations Sandra Misale! @sandramisale.bsky.social! It was nice meeting you last night. #AACR25

Check out this thread from @seplon.bsky.social and then go see the pediatric cancer series here brnw.ch/21wSeVa
#AACR25

If you enjoyed the session “Cancer Predisposition in Childhood Cancer: Implications for Prevention, Surveillance, Interception, and Survivorship Care ", then check out the recent series on the topic in Clinical Cancer Research. #AACR25 brnw.ch/21wSeVa

Just before landing in Chicago, above a sea of fluffy clouds. #AACR25

Are you attending #AACR25 and are thinking about submitting your work to Clincal Cancer Research? Come meet the Editor-in-Chief, Timothy Yap and Executive Editor, Marlowe Tessmer at South Hall A1-2 Booth 2615 Monday 4/28 at 2:00PM. Or contact us to discuss your research.

See you in Chicago.

Hot off the press in Clinical Cancer Research -
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials aacrjournals.org/clincancerre...

The cover shows a portion of a gastric cancer biopsy from a HER2+ patient. For details, see the article by Lim and colleagues on page 1476 of this issue of Clinical Cancer Research.

When you are planning your itinerary for #AACR25, don't forget to contact me and schedule a time so we can talk about submitting your work to Clinical Cancer Research or any questions that you have about the Journal.

See you in Chicago!

The cover shows adjacent normal rectal tissue that was fixed and stained with antibodies to Ki-67 (green) and K-18 (red) with DAPI (blue). For more information, see the article by Chaudhary and colleagues in this issue of Clinical Cancer Research.

March is #MultipleMyelomaAwarenessMonth. AACR Project GENIE offers valuable insights into the genomic landscape of multiple myeloma, with 1,167 patients and 1,548 sequenced tumor samples. #AACRGENIE: www.aacr.org/professional... Powering the future of precision oncology.

Before you come see The CheckPoints perform at the #AACR25 Annual Reception in Chicago next month, learn more about each of the cancer researchers and oncologists who make up this cover band: www.aacr.org/blog/2025/03... #AACRBlog

This cover shows the localization of MUC16 in the membrane & cytoplasmic compartments of a renal medullary carcinoma cell. DNA is blue, MUC16 is green, & actin is red, with merged MUC16 & actin appearing as yellow. For details, see the article by Grimm & colleagues on page 1057 of this issue of CCR.

Women in Cancer Research Women in Cancer Research (WICR) is a membership group within the AACR committed to recognizing women's scientific achievements.

Today is #InternationalWomensDay. Through grants, education and training, and our Women in Cancer Research constituency group, the AACR is committed to inspiring and advancing #WomenInScience. Learn more: buff.ly/8UfcvFz

The AACR is proud to announce our newly elected class of Fellows of the AACR Academy. The AACR Academy honors distinguished scientists whose contributions have propelled significant innovation and progress against cancer. Learn more: buff.ly/8a8WUn9 #AACRFellows

March 7: The Week in Cancer News | Cancer Today HPV vaccine credited for 80% drop in lesions that can lead to cervical cancer, and FDA approves targeted therapy for esophageal cancer.

The Week in Cancer News:
The number of lesions that can lead to cervical cancer has dropped 80% since the introduction of HPV vaccines, the FDA approved a monoclonal antibody to treat esophageal cancer, and more. buff.ly/V4PNnFu

Just out in Clinical Cancer Research - A novel combination of Zanubrutinib plus Ixazomib and Dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia from a phase II clinical trial
aacrjournals.org/clincancerre...

The authors evaluate the paradigm for dietary supplement marketing & FDA approval & its impact on the treatment of cancer patients.
Integrating Botanicals into Oncology Care: Consideration of FDA Regulation of Botanical Products and Botanical Clinical Trials aacrjournals.org/clincancerre...

This cover image shows staining of MUC5AC (green) colocalizing with cMET (red) in breast cancer brain metastatasis. Data suggests a new potential therapeutic target. For details, see the article by Maurya & colleagues in the March 1 issue of Clinical Cancer Research. aacrjournals.org/clincancerre...

Cool cover image showing a turmor section from a patient with advanced head & neck squamous cell carcinoma. Immunohistochemical staining highlights the tumor microenvironment spatial architecture & various immune cell populations surrounding the tumor. See the article by Hanna and colleagues in CCR.

First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr–Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies AbstractPurpose:. A first-in-human phase I study was conducted in patients with nasopharyngeal carcinoma to assess the safety and tolerability of VK-2019, a small-molecule selective inhibitor of Epste...

Clinical Trial of EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr–Positive Nasopharyngeal Cancer with Pharmacokinetic & pharmacodynamic shows an acceptable safety profile, and on-target biological activity in tumors from advanced EBV-positive NPC patients.
aacrjournals.org/clincancerre...

Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models AbstractPurpose:. Datopotamab deruxtecan (Dato-DXd) is a humanized anti–trophoblast cell-surface antigen-2 (TROP2) IgG1 mAb linked to a potent topoisomerase I inhibitor payload (DXd). Dato-DXd has alr...

Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models @mdanderson.bsky.social @theaacr.bsky.social aacrjournals.org/clincancerre...